钌树枝状大分子与抗癌药物联合治疗人类白血病细胞

Combined therapy of ruthenium dendrimers and anti-cancer drugs against human leukemic cells.

作者信息

Michlewska Sylwia, Maroto Marta, Hołota Marcin, Kubczak Malgorzata, Sanz Del Olmo Natalia, Ortega Paula, Shcharbin Dzmitry, de la Mata Francisco Javier, Bryszewska Maria, Ionov Maksim

机构信息

Laboratory of Microscopic Imaging & Specialized Biological Techniques. Faculty of Biology & Environmental Protection. University of Lodz, Banacha12/16, Lodz 90-237, Poland.

Universidad de Alcalá. Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain.

出版信息

Dalton Trans. 2021 Jul 13;50(27):9500-9511. doi: 10.1039/d1dt01388b.

DOI:10.1039/d1dt01388b

PMID:34254615

Abstract

Carbosilane ruthenium(ii) dendrimers have been complexed with conventional anti-cancer drugs. Due to its features, the presence of ruthenium within a dendrimer structure improves the anti-cancer properties of nanocomplexes containing 5-flurouracyl, methotrexate and doxorubicin. These dendrimers could be promising carriers of anti-cancer medicines. Ruthenium dendrimers that are positively charged can also enhance the cytotoxicity to cancer cells; moreover, they can form stable complexes with drugs. Results indicate that ruthenium dendrimers combined with doxorubicin and methotrexate significantly reduced the viability of leukaemia 1301 and HL-60 cancer cells.

摘要

碳硅烷钌（II）树枝状大分子已与传统抗癌药物络合。由于其特性，树枝状大分子结构中钌的存在提高了含有5-氟尿嘧啶、甲氨蝶呤和阿霉素的纳米复合物的抗癌性能。这些树枝状大分子可能是有前途的抗癌药物载体。带正电荷的钌树枝状大分子还可以增强对癌细胞的细胞毒性；此外，它们可以与药物形成稳定的复合物。结果表明，钌树枝状大分子与阿霉素和甲氨蝶呤联合使用可显著降低白血病1301和HL-60癌细胞的活力。